Connect with us

News

DHL Express invests ~EUR750 million in Asia Pacific on the back of e-commerce growth

gbafNews28

  • From 2020 to 2022, DHL Express Asia Pacific is spending close to EUR 690 million on infrastructure build across key markets in the region to increase capacity and efficiency
  • Approximately EUR 60 million has been committed to boost its air network with new aircraft and new routes
  • DHL Express is ready for historic 2020 peak season with 30-40% increase in shipment volume expected

SINGAPORE – Media OutReach – 12 November 2020 – DHL Express, the world’s leading express service provider, announced today that it is investing circa EUR 690 million between 2020 and 2022 to build or expand its facilities in key growth markets of Australia, Japan, Hong Kong S.A.R. and South Korea. Equally, it intends to spend close to EUR 60 million to bolster its Asia Pacific air network such as introducing direct, new (e.g. Vientiane, Yangon), and frequent (e.g. Oceania) flight routes.

[View Image]

 

DHL Express expects shipment volumes in Asia Pacific to be 30-40% larger than last year’s peak season, which typically starts around November and lasts until Lunar New Year. “These investments are testament to our continued confidence in the region. They are crucial not only in the near term as we expect to tackle an unusually strong peak season, but it will make sure that we are well-positioned in the long run to keep global trade running as e-commerce and cross-border trade grow,” said Ken Lee, CEO of DHL Express Asia Pacific.

 

The expanded infrastructure and new flight routes across Asia Pacific will help the company tackle the unprecedented growth in shipment volume and address the ever-growing demand for time-definite express deliveries. Since the start of 2020, DHL Express has experienced a 50% surge in e-commerce shipments in Asia Pacific (excluding China).

 

North Asia investments

The Osaka Distribution Center in Japan scheduled to be opened by the end of 2020 will be DHL Express’ largest distribution facility in the country. With an investment of EUR 71.4 million, it will have 21,000 square meters (sqm) of floor space and is equipped with a state-of-the-art sorting system and X-ray inspection machines.

 

The company’s Central Asia Hub (CAH) in Hong Kong S.A.R., one of DHL Express’ three global hubs, has a EUR 377 million expansion underway that will boost warehouse space by 50% to 47,000 sqm and increase the hub’s annual throughput to 125,000 pieces per day. This means that the hub will be handling six times more in terms of shipment volume than when it was first opened in 2004.

 

Furthermore, a EUR 131 million planned investment in a gateway facility in Incheon, Seoul, South Korea will boost shipment processing capacity by approximately 160%, equipping it to service demand from some of the region’s most advanced economies. The expansion will almost triple the facility’s gross floor area to 58,700 sqm, making it DHL Express’ largest gateway in Asia Pacific.

 

South & Southeast Asia investments

In Bangladesh, DHL Express is investing ~EUR 25 million to build a new facility that will combine its country office and service center into a 10,000 sqm site. The new facility will bring about an approximate 35% increase in shipment processing capacity, and is expected to be opened in Q1 2022. The new Kuala Lumpur Gateway in Malaysia, which is almost triple the size of DHL Express’ current facility, will increase the company’s processing capacity by more than 200%. The EUR 39.4 million facility will be situated at the Kuala Lumpur International Airport and is scheduled to be completed by 2022. At the same time, construction of a new gateway facility in Bangalore, India is underway, slated to be ready by 2021.

 

Utilizing a brand new Boeing 777-200LRF with a capacity of up to 102 tons, DHL Express now flies four times a week from its US hub in Cincinnati and the Los Angeles gateway to the DHL Express South Asia Hub in Singapore, via Sydney. The dedicated route shortens transit time for shipments to and from the US, and allows DHL to operate with greater efficiency while meeting the mounting demand for express deliveries.

 

Oceania investments

Many SMEs in Australia and New Zealand, which have traditionally relied on economy services, are increasingly switching to express delivery services. This trend has led to a more than 40% increase in DHL Express Australia’s inbound and outbound volumes since May 2020. DHL Express has significantly increased its number of dedicated flights to and from Australia to around 30 regular services per week, compared to 10 before the Covid-19 pandemic hit. This includes a new flight that connects Melbourne, Auckland and Christchurch, as well as a new 4x-a-week flight between Hong Kong S.A.R. and Sydney.

 

In September, the company launched its EUR31 million Sydney Service Center, which is double the size of the previous facility and is equipped with an automated high-speed sorting system that processes up to 4,300 shipments per hour. By end 2021, DHL Express will kick start operations at the expanded Brisbane Gateway and Service Center, in which the company will spend EUR 13.2 million to increase floor space by 148% and double its processing capacity. New and expanded facilities are also being planned for Melbourne and Adelaide in the near future. 

 

“The pandemic has caused unparalleled changes to the air cargo industry and it will likely take a long time for the industry to recover to pre-pandemic levels. But having a dedicated fleet and well-implemented contingency plans have helped to keep our network fully operational despite the overnight disappearance of commercial air belly cargo space. The growth in e-commerce shipment volumes will continue to outpace the available air cargo capacity in the industry, strengthening the case to invest in adding new dedicated aircraft to our fleet, open up new routes, and supplement our fleet with charter flights,” said Sean Wall, Executive Vice President, Network Operations & Aviation, DHL Express Asia Pacific.

 

DHL Express currently has 23 dedicated aircraft in its Asia Pacific fleet, and operate approximately 1,040 flights per day. The company will be adding a new Airbus A330-300P2F to its Asia Pacific fleet in February 2021, as well as a new Boeing 737-800F in March 2021. Globally, the company has increased the number of its daily flights significantly. This includes four new Boeing 777F wide-body aircraft that were put into service just this year, with two more expected to be delivered next month. These six additional aircraft will enable DHL Express to carry out more than 3,000 additional intercontinental flights per year.

 

DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 380,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

 

DHL is part of Deutsche Post DHL Group. The Group generated revenues of more than 63 billion euros in 2019. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. Deutsche Post DHL Group aims to achieve zero-emissions logistics by 2050.

News

Sarah Cannon to Present Latest in Blood Cancer Research at the 62nd ASH Annual Meeting & Exposition

gbafNews28

Today, Sarah Cannon announced that 53 abstracts and presentations authored by Sarah Cannon experts have been selected for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition. Held virtually December 5-8, 2020, the ASH Annual Meeting & Exposition will bring together thought leaders from across the globe to discuss innovative research in malignant and non-malignant blood cancer.

Our network of experts are excited to share the latest advancements in blood cancer research at this years ASH Annual Meeting and Exposition, including important advances in CAR T-Cell Therapy and data from innovative studies for beta thalassemia and sickle cell disease, says Fred LeMaistre, MD, Physician-in-Chief of Blood Cancers, Sarah Cannon. We look forward to virtually coming together with experts from around the world to discuss the pivotal research and cutting-edge therapies that are changing the way we treat blood cancer.

Haydar Frangoul, MD, MS, Medical Director, Pediatric Hematology/Oncology, Sarah Cannon Center for Blood Cancer at The Childrens Hospital at TriStar Centennial, will present ˜Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9“Modified CD34+ Hematopoietic Stem and Progenitor Cells during the Plenary Scientific Session on December 6 from 7-9am PST. Dr. Frangoul will also discuss this research during a press briefing as part of the 62nd ASH Annual Meeting Press Program taking place on December 5 from 9:30-10 a.m. PST.

Aravind Ramakrishnan, MD, Medical Director of Adult Blood and Marrow Transplant, Texas Transplant Institute at the Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center, will present ˜Phase 1 Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory (r/r) DLBCL in an oral presentation on December 7 from 9-10:30 a.m. PST.

Additionally, Ian Flinn, MD, PhD, Director of Lymphoma Research, Sarah Cannon Research Institute, will chair the Satellite Symposia ˜Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes on December 4 from 7:30-9 a.m. PST and Jesus G. Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, will participate in an Education Session on ˜The Emerging Role of Targeted Therapies and Cell Therapy in Transplant – Live Q&A on December 5 from 2-2:45 p.m. PST.

The 53 abstracts and presentations represent studies being conducted by investigators from Sarah Cannon Blood Cancer Network and Sarah Cannon Research Institute in affiliation with: Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center- HealthONE in Denver, Florida Cancer Specialists, Texas Oncology at Medical City Dallas in Dallas, Private Care at Guys at London Bridge Hospital in London, UK, Sarah Cannon Blood Cancer Center at Research Medical Center in Kansas City, Mo., Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center in Austin, Texas, Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center in Nashville, Tenn., Texas Transplant Institute at Methodist Hospital in San Antonio, Texas, Tulane Medical Center in New Orleans, and University of Oklahoma Medical Center in Oklahoma City.

Additionally, ASH Annual Meeting & Exposition posters with Sarah Cannon Blood Cancer Network experts as first authors will be presented by:

  • Carlos Bachier, MD, Director of Cellular Therapy Research, Sarah Cannon Research Institute; Program Director, Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center, will present on ˜A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS) on December 5 from 7am-3:30 p.m. PST and ˜Costs and Adverse Events Associated with Ibrutinib or Ruxolitinib in Chronic Graft-Versus-Host Disease on December 7 from 7 a.m.-3:30 p.m. PST.
  • Minoo Battiwalla, MD, MS, Director of Outcomes Research, Sarah Cannon, will present on ˜Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN) on December 7 from 7 a.m.-3:30 p.m. PST.
  • Dr. Berdeja will present on ˜Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis on December 5 from 7 a.m.-3:30 p.m. PST.
  • William Donnellan, MD, Director of Leukemia/Myelodysplastic Syndrome Research, Sarah Cannon Research Institute, will present on ˜Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) “ Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications on December 6 from 7 a.m.-3:30 p.m. PST.
  • Dr. Flinn will present on ˜Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study on December 7 from 7 a.m.-3:30 p.m. PST.
  • Henning Schade, MD, Assistant Member Physician, Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center “ HealthONE, will present on ˜HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma on December 5 from 7 a.m.-3:30 p.m. PST.

About The Sarah Cannon Blood Cancer Network

The Sarah Cannon Blood Cancer Network offers patients convenient, community-based access to complex blood cancer care including blood and marrow transplantation (BMT), clinical trials and innovative therapies such as CAR T-Cell Therapy. The Sarah Cannon Blood Cancer Network brings together physician-led blood cancer programs across the United States and United Kingdom and is one of the largest providers of BMT. In fact, it conducts more than 1,200 transplants annually through eight FACT/JACIE accredited transplant centers and has performed more than 14,000 transplants since inception of its first program. The Sarah Cannon Blood Cancer Network programs include Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center in Austin, Texas, Medical City Dallas in Dallas, Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center- HealthONE in Denver, Sarah Cannon Blood Cancer Center at Research Medical Center in Kansas City, Mo., Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center in Nashville, Tenn., Texas Transplant Institute at Methodist Hospital in San Antonio, HCA Healthcare UK at University College Hospital, Private Care (London), Private Care at Guys at London Bridge Hospital (London) and The Christie Private Care, part of HCA Healthcare UK (Manchester). For more information about the Network and Sarah Cannons full suite of oncology services, visit sarahcannon.com.

Becca Gelman

[email protected]

Continue Reading

News

Children’s Hospital Los Angeles Offers FREE Flu Vaccination Family Clinic

gbafNews28

Childrens Hospital Los Angeles:

WHAT:

Get your free flu shot at select CHLA Specialty Care Centers. No appointment needed. Available for the whole family. www.CHLA.org/events

 

 

 

 

WHY:

The American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America recommends everyone over 6 months of age receive the flu vaccine every year. With COVID-19 numbers still at dangerous levels, its now more crucial than every to be vigilant about your familys health.

 

 

 

 

WHEN:

Saturday, December 5

 

 

Saturday, December 12

 

 

Saturday, December 19

 

 

 

 

 

9 a.m. “ 3 p.m.

 

 

 

 

WHERE:

Walk-up clinic

 

  • South Bay “ 3440 Torrance Blvd., Torrance, CA 90503 (in the main lobby)

Drive-up clinics

  • Arcadia “ 468 E. Santa Clara St., Arcadia, CA 91006
  • Encino “ 5363 Balboa Blvd., Encino, CA 91316
  • Valencia “ 23838 Valencia Blvd., Valencia, CA 91355

 

(PRESS ONLY)

Lauren Song, [email protected] or 323-203-6737

Continue Reading

News

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fortress Biotech, Inc. (FBIO) Investors

gbafNews28

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fortress Biotech, Inc. (Fortress or the Company) (NASDAQ: FBIO) securities between December 11, 2019 and October 9, 2020 inclusive (the Class Period). Fortress investors have until January 26, 2021 to file a lead plaintiff motion.

If you suffered a loss on your Fortress investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/fortress-biotech-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Fortress develops and commercializes pharmaceutical and biotechnology products. In December 2019, the Company’s majority-controlled subsidiary, Avenue Therapeutics, Inc. (“Avenue”), submitted a New Drug Application (“NDA”) for its intravenous (“IV”) Tramadol product to the U.S. Food and Drug Administration (“FDA”) for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

On October 12, 2020, Avenue disclosed receipt of a Complete Response Letter (“CRL”) from the FDA regarding the NDA for its IV Tramadol product. Specifically, the FDA advised Avenue that “it cannot approve the application in its present form” because “IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population.” Specifically, the CRL stated: “[I]f a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed. The likely choice would be another opioid, which would result in opioid ‘stacking’ and increase the likelihood of opioid-related adverse effects.”

On this news, Fortress’s stock price fell $1.00 per share, or 23.98%, to close at $3.17 per share on October 12, 2020, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Fortress securities during the Class Period, you may move the Court no later than January 26, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to¯learn more¯about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News16 mins ago

Sarah Cannon to Present Latest in Blood Cancer Research at the 62nd ASH Annual Meeting & Exposition

Today, Sarah Cannon announced that 53 abstracts and presentations authored by Sarah Cannon experts have been selected for presentation at...

gbafNews28 gbafNews28
News20 mins ago

Road Stud and Delineator Market is Expected to Witness Market Growth Due to the Increasing Incidents of Road Accidents | Technavio

The global road stud and delineator market size is poised to grow by USD 399.73 million during 2020-2024, progressing at...

gbafNews28 gbafNews28
News20 mins ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of K12 Inc. (LRN) Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has...

gbafNews28 gbafNews28
News20 mins ago

Global Semiconductor Alliance (GSA) Announces its 2020 Award Recipients

The Global Semiconductor Alliance (GSA) is proud to announce the award recipients honored at this years GSA Awards Virtual Ceremony...

gbafNews28 gbafNews28
News20 mins ago

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff...

gbafNews28 gbafNews28
News20 mins ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fortress Biotech, Inc. (FBIO) Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has...

gbafNews28 gbafNews28
News20 mins ago

Children’s Hospital Los Angeles Offers FREE Flu Vaccination Family Clinic

Childrens Hospital Los Angeles: WHAT: Get your free flu shot at select CHLA Specialty Care Centers. No appointment needed. Available...

gbafNews28 gbafNews28
News23 mins ago

Zynx Health Updates and Expands Its Free-of-Charge COVID-19 Clinical Decision Support

Zynx Health today announced that it has significantly expanded and updated the publicly accessible COVID-19 clinical decision support available on...

gbafNews28 gbafNews28
News36 mins ago

AM Best Posts Interactive Webinar Highlights for “How Active Risk Management Drives Better Customer Engagement”

Viewers can access highlights from an AM Best webinar sponsored by LexisNexis Risk Solutions to learn how active risk management...

gbafNews28 gbafNews28
News44 mins ago

Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World

Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication...